Agree DB. You don't need a 100% responder rate to have a...

Agree DB. You don't need a 100% responder rate to have a valuable drug.. comes down to what is the treatment effect size, clinical benefit, side effect profile and are there any substitute therapies.. So for DMX-200, so far we know that the effect size in some is large (>50% reduction over standard of care), good data to show that reduction in proteinuria leads to better clinical outcomes, side effect profile is excellent (two marketed drugs), and there aren't any other good treatments out there.. so ticks all four boxes. The value of the licensing deal I believe then will be correlated then with what is the responder rate.. eg maybe at 20% it's $200-300M, at 30% maybe $400-500M .. not sure.. but wouldn't be too far from that mark I would think.. As KH says.. "exciting times.."